Suppr超能文献

骨化三醇3μg/g软膏局部应用治疗轻度至中度银屑病:一项开放标签研究的结果

Topical use of calcitriol 3 microg/g ointment in the treatment of mild-to-moderate psoriasis: results from an open-label study.

作者信息

Carboni I, de Felice C, Bergamin A, Chimenti S

机构信息

Department of Dermatology, University of Rome "Tor Vergata", Italy.

出版信息

J Eur Acad Dermatol Venereol. 2005 Nov;19 Suppl 3:11-3. doi: 10.1111/j.1468-3083.2005.01331.x.

Abstract

BACKGROUND

Calcitriol is the active metabolite and hormonal analogue of vitamin D3. It is widely used for the topical treatment of psoriasis showing good tolerability and effectiveness.

OBJECTIVES

To assess the efficacy, tolerability and safety of calcitriol 3 microg/g ointment in mild to moderate plaque psoriasis involving sensitive areas.

METHODS

Sixty patients with a body surface area < 35% were enrolled into a prospective open label clinical study. Patients were treated for 12 weeks with a twice daily calcitriol 3 microg/g topical ointment application. Efficacy and safety were assessed during the therapy and during a 6-month follow-up period.

RESULTS

The study demonstrated a high clinical remission rate which progressively increased throughout therapy (11.6% at week 4, 28.3% at week 8 and 63.3% at week 12). No serious adverse events and clinically relevant changes of calcium/phosphorus homeostasis were reported.

CONCLUSIONS

The study suggests that calcitriol 3 microg/g ointment, applied twice daily, is an effective topical treatment for chronic psoriatic plaques involving less than 35% of the body surface and sensitive areas.

摘要

背景

骨化三醇是维生素D3的活性代谢产物和激素类似物。它广泛用于银屑病的局部治疗,显示出良好的耐受性和有效性。

目的

评估3μg/g骨化三醇软膏治疗累及敏感区域的轻至中度斑块状银屑病的疗效、耐受性和安全性。

方法

60例体表面积<35%的患者纳入一项前瞻性开放标签临床研究。患者每日两次外用3μg/g骨化三醇软膏,治疗12周。在治疗期间和6个月的随访期内评估疗效和安全性。

结果

研究显示临床缓解率较高,在整个治疗过程中逐渐升高(第4周为11.6%,第8周为28.3%,第12周为63.3%)。未报告严重不良事件及钙/磷稳态的临床相关变化。

结论

该研究表明,每日两次外用3μg/g骨化三醇软膏是治疗累及体表面积小于35%且为敏感区域的慢性银屑病斑块的有效局部治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验